

Please substitute the following for the paragraph of page 13, lines 1 – 11.

-- phenylacetamide, N-[1-benzyl-4-(6-methyl-2-pyridinyl)-4-piperidinyl]-N-phenylacetamide, N-[1-benzyl-4-(6-methyl-2-pyridinyl)-4-piperidinyl]-2,2,2-trifluoro-N-phenylacetamide, N-[1-(4-fluorobenzyl)-4-(4-methylthiazol-2-yl)-4-piperidinyl]-N-phenylacetamide, N-[1-benzyl-4-(4-methylthiazol-2-yl)-4-piperidinyl]-N-(2-methylphenyl)acetamide, N-[1-benzyl-4-(4-methylthiazol-2-yl)-4-piperidinyl]-N-(3-chlorophenyl)acetamide, N-[4-(4-methylthiazol-2-yl)-1-(2-thienylmethyl)-~~2-yl~~]-4-piperidinyl]-N-phenylacetamide, N-[1-benzyl-4-(1-methyl-1H-imidazol-2-yl)-4-piperidinyl]-N-phenylacetamide, or a salt thereof, --


Please substitute the following for the paragraph of page 62, lines 1 – 6.

-- chlorophenyl)acetamide (Reference Example 82A, B), N-[4-(4-methylthiazol-2-yl)-1-(2-thienylmethyl)-~~2-yl~~]-4-piperidinyl]-N-phenylacetamide (Reference Example 48), and N-[1-benzyl-4-(1-methyl-1H-imidazol-2-yl)-4-piperidinyl]-N-phenylacetamide (Reference Example 50) or a salt thereof are preferable.--

In the Claims

Please amend the claims to read as follows, without prejudice to future continuing applications.


1. (ORIGINAL) A composition for regulating neuromedin U receptor, which comprises a compound having a partial structure represented by the formula:



wherein ring Xa represents a nitrogen-containing nitrogen-containing ring, and R represents an optionally substituted amino group, or a salt thereof.


2. (ORIGINAL) The composition according to claim 1, which comprises a compound having an aminopiperidine skeleton or a salt thereof.

3. (ORIGINAL) The composition according to claim 1, which comprises a compound represented by the formula:




wherein ring Xb represents an optionally further substituted 5 to 8-membered nitrogen-containing ring, Y represents an optionally substituted ring group, and Q² represents an acyl group, or a salt thereof or a prodrug thereof.

4. (ORIGINAL) The composition according to claim 1, which comprises a compound represented by the formula:



wherein ring X represents an optionally further substituted piperidine ring, Y represents an optionally substituted ring group, Q^1 represents a hydrogen atom or a substituent, and Q^2 represents an acyl group, or a salt thereof or a prodrug thereof.

5. (ORIGINAL) The composition according to claim 1, which comprises a compound represented by the formula:



wherein A represents an optionally substituted ring group, B represents an optionally substituted phenyl group, ring D represents an optionally further substituted piperidine ring, Z represents an optionally substituted methylene group, $-\text{COCH}_2-$, $-\text{CH}_2\text{CO}-$ or $-\text{SO}_2-$, R^1 represents a hydrogen atom, a cyano group, an optionally substituted lower alkyl group, an optionally substituted phenyl group, an optionally substituted aromatic heterocyclic group, an optionally esterified carboxyl group or an optionally substituted carbamoyl group, and R^2 represents an optionally substituted lower alkyl group, an optionally substituted lower alkenyl group, an optionally substituted lower


alkoxy group, an optionally substituted aralkyloxy group or an optionally substituted phenyl group, or a salt thereof or a prodrug thereof.

6. (ORIGINAL) The composition according to claim 1, which is an antagonist of a neuromedin U receptor FM-3.

7. (ORIGINAL) The composition according to claim 1, which is a composition for regulating physiological function in which neuromedin U is involved, or a preventive/therapeutic agent for morbid state or disease in which neuromedin U is involved.


8. (ORIGINAL) The composition according to claim 1, which is a preventive/therapeutic agent for hypertension, cardiac infarct, acute renal dysfunction, angina, cardiac infarct, arrhythmia, bronchial asthma, hyperpnea syndrome, rheumatoid arthritis, diabetes, climacteric disorder, immune activity reduction, stomach ulcer or ulcerative colitis, or a composition for regulating an appetite.

9. (ORIGINAL) A method of regulating function of a neuromedin U receptor, which comprises administering an effective amount of a compound having a partial structure represented by the formula:




wherein ring Xa represents a nitrogen-containing ring, and R represents an optionally substituted amino group, or a salt thereof to a mammal.

10. (ORIGINAL) Use of a compound having a partial structure represented by the formula:



wherein ring Xa represents a nitrogen-containing ring, and R represents an optionally substituted amino group, or a salt thereof for preparing a composition for regulating neuromedin U receptor.

11. (ORIGINAL) A compound represented by the formula:



wherein ring D represents an optionally further substituted piperidine ring, E represents an optionally substituted phenyl group, Z¹ represents a methylene group optionally substituted with a substituent selected from the group consisting of lower alkyl, lower alkoxy carbonyl, oxo and phenyl, -COCH₂-, -CH₂CO- or -SO₂-, R^{1b} represents an optionally substituted 2-thiazolyl group, an optionally substituted 2-imidazolyl group or an optionally substituted 2-pyridyl group, R^{2b} represents an optionally halogenated lower alkyl group, and R³ represents an optionally substituted phenyl group, an optionally substituted aromatic heterocyclic group or an optionally substituted cycloalkyl group, provided that N-[1-benzyl-4-(4-methylthiazol-2-yl)-4-piperidinyl]-N-phenylpropionamide and N-[1-benzyl-4-(2-pyridinyl)-4-piperidinyl]-N-phenylpropionamide are excluded, or a salt thereof.

12. (ORIGINAL) The compound according to claim 11, wherein R³ is an optionally substituted phenyl group or an optionally substituted thienyl group.

13. (ORIGINAL) The compound according to claim 11, wherein R³ is a phenyl group.
14. (ORIGINAL) The compound according to claim 11, wherein E is a phenyl group optionally having a substituent at an ortho position or a meta position.
15. (ORIGINAL) The compound according to claim 11, wherein E is an unsubstituted phenyl group.
16. (ORIGINAL) The compound according to claim 11, wherein R^{1b} is a 2-thiazolyl group optionally substituted with a lower alkyl group.
17. (ORIGINAL) The compound according to claim 11, wherein R^{1b} is a 4-methyl-2-thiazolyl group.
18. (ORIGINAL) The compound according to claim 11, wherein R^{1b} is a 2-pyridyl group optionally substituted with a substituent selected from the group consisting of a lower alkyl group, a lower alkylthio group, a halogen atom, a C₆₋₁₄ aryl group and an aromatic heterocyclic group.
19. (ORIGINAL) The compound according to claim 11, wherein R^{1b} is a 6-methyl-2-pyridyl group.
20. (ORIGINAL) The compound according to claim 11, wherein Z¹ is a methylene group optionally substituted with a lower alkyl group.
21. (ORIGINAL) The compound according to claim 11, wherein Z¹ is a methylene group.
22. (ORIGINAL) The compound according to claim 11, wherein R^{2b} is an optionally halogenated methyl group or ethyl group.
23. (ORIGINAL) The compound according to claim 11, wherein R^{2b} is a methyl group or a trifluoromethyl group.

24. (ORIGINAL) The compound according to claim 11, wherein ring D is a piperidine ring optionally further substituted with a lower alkyl.

25. (ORIGINAL) The compound according to claim 11, wherein ring D is a piperidine ring optionally further substituted with C₁₋₆ alkyl, E is a phenyl group optionally substituted with a substituent selected from the group consisting of a halogen atom and C₁₋₆ alkyl, Z¹ is a methylene group optionally substituted with a substituent selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkoxy carbonyl, oxo and phenyl, -COCH₂- or -SO₂-, R^{1b} is (i) a 2-thiazolyl group optionally substituted with C₁₋₆ alkyl, (ii) a 2-imidazolyl group optionally substituted with C₁₋₆ alkyl, or (iii) a 2-pyridyl group optionally substituted with a substituent selected from the group consisting of C₁₋₆ alkyl, a halogen atom, C₁₋₆ alkylthio, phenyl and thienyl, R^{2b} is an optionally halogenated C₁₋₆ alkyl group, R³ is (i) a C₃₋₈ cycloalkyl group, (ii) a phenyl group or (iii) a 5- to 10-membered aromatic heterocyclic group containing one or two kinds of 1 to 4 hetero atoms selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to carbon atoms, which may be substituted with a substituent selected from the group consisting of a halogen atom, cyano, C₁₋₆ alkyl optionally substituted with a halogen atom, C₁₋₆ alkoxy optionally substituted with a halogen atom, C₁₋₆ alkyl-carbonylamino, a 5- or 6-membered aromatic heterocyclic group and C₁₋₆ alkylthio.

26. (CURRENTLY AMENDED) N-[1-benzyl-4-(4-methylthiazol-2-yl)-4-piperidinyl]-N-phenylacetamide, N-[1-benzyl-4-(4-methylthiazol-2-yl)-4-piperidinyl]-2,2,2-trifluoro-N-phenylacetamide, N-[1-benzyl-4-(6-methyl-2-pyridinyl)-4-piperidinyl]-N-phenylacetamide, N-[1-benzyl-4-(6-methyl-2-pyridinyl)-4-piperidinyl]-2,2,2-trifluoro-N-phenylacetamide, N-[1-(4-fluorobenzyl)-4-(4-methylthiazol-2-yl)-4-piperidinyl]-N-phenylacetamide, N-[1-benzyl-4-(4-methylthiazol-2-yl)-4-piperidinyl]-N-(2-methylphenyl)acetamide, N-[1-benzyl-4-(4-methylthiazol-2-yl)-4-piperidinyl]-N-(3-

chlorophenyl)acetamide, N-[4-(4-methylthiazol-2-yl)-1-(2-thienylmethyl)-~~2-yl~~]-4-piperidinyl]-N-phenylacetamide, N-[1-benzyl-4-(1-methyl-1H-imidazol-2-yl)-4-piperidinyl]-N-phenylacetamide, or a salt thereof.

27. (ORIGINAL) A prodrug of the compound according to claim 11 or 26 or a salt thereof.

28. (ORIGINAL) A medicine comprising the compound according to claim 11 or 26 or a salt thereof or a prodrug thereof.